A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae097 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Adrianna Zara Herskovits und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Chemokine CXCL9, Receptors, Interleukin-2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objectives
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by a massive overactivation of the immune system. Because the clinical findings are nonspecific, the development of assays to facilitate rapid diagnosis is critical for patient care. The objectives of this study were to evaluate the performance of a microfluidic enzyme-linked immunosorbent assay (ELISA) for HLH biomarkers and investigate the impact of insourcing this testing on workflow, cost, and turnaround time in a tertiary-care cancer hospital.
Methods
Trends in order volume were evaluated for C-X-C motif chemokine ligand 9 (CXCL9) and soluble interleukin 2 receptor ɑ (sIL2R), and a microfluidic ELISA was used to measure these analytes in serum samples. Analyte values, turnaround time, and costs were compared for this assay relative to reference laboratory testing.
Results
Test ordering has increased from 187 to 1030 requests annually over the past 5 years. Insourcing these analytes on a semiautomated ELISA can decrease time to result by approximately 2 days and generate a cost savings of roughly $140,000 annually within our laboratory.
Conclusions
Using a semiautomated ELISA for sIL2R and CXCL9 may help physicians arrive at a diagnosis and monitor therapy for patients with HLH while decreasing turnaround time and costs within the clinical laboratory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US.
- Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US.
- Division of Transplantation & Cellular Therapies, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, US.
Förderung
- FDA HHS
- NCI NIH HHS
- NIH HHS
- Food and Drug Administration
- National Institutes of Health
- National Cancer Institute Cancer Center
Zitieren
APA
Herskovits, A. Z., Johnson, W. T., Oved, J. H., Irwin, S., Doddi, S., John, D., Ocasio, A., & Ramanathan, L. V. (2025). A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae097
Vancouver
Herskovits AZ, Johnson WT, Oved JH, Irwin S, Doddi S, John D, et al. A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae097
BibTeX
@article{Herskovits2025,
author = {Herskovits, Adrianna Zara and Johnson, William T and Oved, Joseph H and Irwin, Spencer and Doddi, Sital and John, Deronna and Ocasio, Angelica and Ramanathan, Lakshmi V},
title = {A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae097}
}
EUVIMED